JDRF To Collaborate with MediGene to Develop an Antigen-Specific Immunotherapeutic for Type I Diabetes
MediGene AG through its wholly owned UK subsidiary in Oxford (formerly Avidex) announced a funded collaborative research program with the Juvenile Diabetes Research Foundation (JDRF). Through its Industry Discovery and Development Partnership Program, JDRF is providing financial support for the advancement of monoclonal T cell receptor (mTCR) therapeutics that aim to prevent the destruction of insulin producing beta cells which occurs with the onset of type I diabetes. JDRF is collaborating with MediGene over two years to accelerate ongoing proof-of-concept studies into the clinic.
Type I diabetes is a disease caused by T cells that inappropriately destroy the body's own insulin-producing cells. MediGene's mTCR therapeutics engineer T cell receptors into antibody-like proteins that can be used to actively target known therapeutic compounds to target tissues. For its type I diabetes program, MediGene is developing specific mTCRs which will be used to both competitively block autoreactive T cell engagement to beta cells and to selectively target known immunosuppressive agents to the beta cell's local environment.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.